Abstract
One in five people suffer from moderate to severe chronic pain, and one in three is unable or less able to maintain an independent lifestyle due to their pain. Between 50 and 60 percent of people with chronic pain are less able or unable to exercise, sleep normally, perform household chores, attend social activities, drive a car, or walk.
The value of the pharmaceutical market for pain relief in 2007 reflects this seeming worldwide epidemic of pain. The Global Pain Therapeutics Market assesses key pain management therapeutics - such as opioids, triptans, anticonvulsants, Cox-II inhibitors and traditional NSAIDs and are discussed in terms of their past, present and future value and the role they are playing in the effective management of pain. This report discusses the key products within each of these areas and outlines the drivers of these markets as well as the restraints on them.
The Global Pain Therapeutics Market also identifies and discusses trends and issues that will have a significant impact on the pain management market and profiles the leading companies in the field. The report provides the reader with valuable information and analysis regarding key products on the market and in clinical development.
This 408-page report includes 96 profiles of companies engaged in the development and/or commercialization of pain therapeutics and over 160 tables and graphs illustrating sales trends, past and present, as well as pipelines and demographic and market trends in the area of pain management.
Key features and highlights of this report:
- Extensive review of key products indicated for pain conditions and their market value and impact
- Discussion of the key drivers of and restraints on the global pain therapeutics market
- Qualitative analysis of key pain markets and products driving growth (opioids, NSAIDs, triptans, neuropathic pain therapies (anticonvulsants) and Cox-II inhibitors)
- Profiles and reviews of key pipeline products in development for fibromyalgia, cancer pain, post-operative pain, migraine pain, neuropathic pain and opioid therapies
- Profiles of nearly 100 companies engaged in the development and/or commercialization of pain therapeutics worldwide
- Overviews of treatment options for post-operative pain, migraine pain, cancer pain, fibromyalgia, arthritic pain, back pain, neuropathic pain, and the demographic impact of these conditions.
- Chapter devoted to the role of drug delivery technologies in the current and future treatment of pain
- Discussion of promising areas of research in a variety of pain areas and companies engaged in cutting edge research and development
Key questions answered in this report:
- What is the current state of the global pain therapeutics market?
- How has the Cox-II debacle effected the market for and treatment of pain conditions?
- What pain therapies, old and new, are today proving their market and clinical value?
- What new classes of pain therapeutics are in clinical development and which classes and therapies are demonstrating superior efficacy?
- Which diseases and conditions have the most room for growth in terms of unmet need and market demand?
Table of Contents
1 METHODOLOGY AND EXECUTIVE SUMMARY
- 1.1 Research Methodology
- 1.2 Report Objectives and Scope
- 1.3 Executive Summary
2 CAUSES, CLASSIFICATIONS AND GLOBAL IMPACT OF PAIN
- 2.1 Causes
- 2.1.1 Terminal Illness
- 2.1.2 Pain and Genetics
- 2.1.3 The Immune System and Pain
- 2.1.4 The Subjective Nature of Pain
- 2.1.5 Pain Transmission
- 2.1.5.1 Nociceptors
- 2.1.5.2 Pain Receptors
- 2.2 Classifications of Pain
- 2.2.1 Chronic Pain
- 2.2.2 Acute Pain
- 2.3 The Impact of Pain
- 2.3.1 Demographic Impact of Pain
- 2.3.2 Financial Cost of Pain
3 TREATING PAIN: DRUG CLASSES AND GUIDELINES
- 3.1 NSAIDs
- 3.2 Opioids
- 3.2.1 Chronic Pain and Opioids
- 3.3 Antidepressants
- 3.4 Anticonvulsants
4 POST-OPERATIVE PAIN OVERVIEW AND THERAPEUTIC OPTIONS
- 4.1 Impact of Post-operative Pain
- 4.2 Pain Intensity in Surgical Sites
- 4.3 Site-Specific Pain Relief
- 4.4 Post-operative Medications
- 4.4.1 Naropin
- 4.4.2 DepoDur, DepoMorphine and Propofol
- 4.4.3 Other Opioids for Pain Management
- 4.4.4 NSAIDs for Post-operative Pain
5 BACK PAIN OVERVIEW AND THERAPEUTIC OPTIONS
- 5.1 Sciatica
- 5.2 Facet Joint Problems
- 5.3 Osteoarthritis
- 5.4 Diseases and Back Pain
- 5.5 Low Back Pain
- 5.6 Pharmaceutical Relief for Back Pain
- 5.6.1 Transdermal Patches
- 5.6.2 Injections for Back Pain
- 5.6.3 Back Pain and Opioids
- 5.6.4 Tricyclic Antidepressants
- 5.6.5 Muscle Relaxers
- 5.6.6 Colchicine
- 5.6.7 Chronic Low Back Pain and Anticonvulsants
6 NEUROPATHIC PAIN OVERVIEW AND THERAPEUTIC OPTIONS
- 6.1 Nociceptive Versus Neuropathic Pain
- 6.2 Nociceptive and Neuropathic Mixed Pain
- 6.3 Neuropathic Pain Generation
- 6.4 Treating Neuropathic Pain
- 6.4.1 Tricyclic Antidepressants
- 6.4.2 Duloxetine
- 6.4.3 Transdermal Fentanyl
- 6.4.4 Tramadol
- 6.4.5 Ketamine and Alfentanil
- 6.4.6 Neurontin
- 6.4.7 Lyrica
- 6.4.8 Carbamazepine
- 6.4.9 Lidocaine
7 MIGRAINE OVERVIEW AND THERAPEUTIC OPTIONS
- 7.1 Impact of Migraines
- 7.2 Pharmacological Treatment of Migraine Pain
- 7.2.1 Fiorinal and Fioricet
- 7.2.2 Ergot Alkaloid Derivatives
- 7.2.3 Triptans
- 7.2.3.1 Comparing Triptans
- 7.2.3.2 Imitrex
- 7.2.3.3 Zomig
- 7.2.3.4 Maxalt
- 7.2.3.5 Relpax
- 7.2.4 Neuroleptics
- 7.2.5 Beta-Blockers
- 7.3 Alternative Therapies for Migraine
8 CANCER PAIN OVERVIEW AND THERAPEUTIC OPTIONS
- 8.1 Causes of Cancer Pain
- 8.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Cancer Pain
- 8.3 Opioids and Cancer Pain
- 8.3.1 Reluctance to Prescribe Opioids
- 8.4 Seizure Drugs for Cancer Pain
9 ARTHRITIC PAIN OVERVIEW AND THERAPEUTIC OPTIONS
- 9.1 Impact of Arthritis
- 9.2 Rheumatoid Arthritis
- 9.2.1 Causes
- 9.2.2 RA Demographics
- 9.2.3 Genetic Susceptibility
- 9.2.4 Environmental Factors
- 9.2.5 High Cost of Rheumatoid Arthritis
- 9.3 Osteoarthritis
- 9.3.1 Causes
- 9.3.2 Pharmacological Treatment of Osteoarthritis
- 9.3.2.1 Cox-2 Class
- 9.3.3 Pharmacological Treatment of Rheumatoid Arthritis
- 9.4 Antirheumatic Drug Classes
- 9.4.1 Nonsteroidal Anti-Inflammatory Drugs
- 9.4.2 Corticosteroids
10 FIBROMYALGIA OVERVIEW AND THERAPEUTIC OPTIONS
- 10.1 Manifestations
- 10.2 Impact of Fibromyalgia
- 10.3 Natural Treatments for Fibromyalgia
- 10.4 Prescription Treatments for Fibromyalgia
- 10.4.1 Treatment with Antidepressants
- 10.4.2 Muscle Relaxants
- 10.4.3 Sleep Modifiers
- 10.4.4 Anxiety Medications
- 10.4.5 Anticonvulsants
- 10.4.6 Antibiotics
11 NON-PHARMACEUTICAL PAIN TREATMENT
- 11.1 Acupuncture
- 11.1.1 Assessing Acupuncture' s Value
- 11.2 Osteopathic Manipulation
- 11.2.1 Osteopathic Treatment
- 11.2.2 Conditions Treated by Osteopaths
- 11.3 Physiotherapy
- 11.4 Reflexology
- 11.5 Neurostructural Integration Technique
- 11.6 Herbal Medicine
- 11.7 Neurolytic Block Injections
- 11.7.1 Examples of Neurolytic Blocks
- 11.8 Chemical Neurolytic Blocks
- 11.9 Cryoablation
- 11.10 Radiofrequency Lesioning
- 11.11 Neurosurgical Procedures
- 11.12 Chemical Ablation
- 11.13 Nerve Blocks
- 11.14 Neurostimulation and Pain Control
- 11.15 Electro Thermal Disc Decompression/ Intradiscal Electro Thermocoagulation
- 11.16 Selective Nerve Root Injections
- 11.17 Facet Joint Pain Block
- 11.18 Trigger Spot Injections
- 11.19 Peripheral Nerve Injections
- 11.20 Cervical and Lumbar Epidural Blocks
- 11.21 Cognitive Behavioral Treatment (CBT)
12 NSAID USE AND MARKET ANALYSIS
- 12.1 Overview
- 12.2 Over-the-Counter NSAIDs
- 12.2.1 Ibuprofen
- 12.2.2 Naproxen
- 12.2.3 Acetaminophen and Aspirin
- 12.3 Traditional Prescription NSAIDs
- 12.3.1 Diclofenac/Cataflam/Voltaren
- 12.3.2 Arthrotec
- 12.3.3 Mobic
- 12.3.3.1 Mobic' s Market Performance
- 12.3.3.2 Mobic Vs Other NSAIDs
- 12.3.4 DayPro
- 12.3.4.1 Rheumatoid Arthritis Relief from DayPro
- 12.3.4.2 Osteoarthritis Relief from DayPro
- 12.3.5 Relafen
- 12.3.5.1 Relafen Versus Naproxen and Aspirin
- 12.3.5.2 Endoscopy Trials
- 12.4 The Future of the NSAID Market
- 12.5 Drivers and Constraints of the NSAID Market
13 OPIOID USE AND MARKET TRENDS
- 13.1 Drawbacks of Opioid Therapy
- 13.2 Treating Chronic Pain
- 13.3 Key Opioid Products
- 13.3.1 Morphine
- 13.3.1.1 Increased Usage of Morphine
- 13.3.1.2 Cognitive and Psychomotor Effects
- 13.3.1.3 Extended Release Morphine
- 13.3.1.3.1 Kadian
- 13.3.1.3.1.1 Kadian and Naltrexone
- 13.3.1.3.1.2 Key Clinical Trial
- 13.3.1.3.1 Kadian
- 13.3.2 Codeine
- 13.3.3 Oxycodone
- 13.3.4 Vicodin
- 13.3.5 Ultracet/Ultram
- 13.3.6 Duragesic
- 13.3.7 Fentora
- 13.3.8 Ionsys
- 13.3.1 Morphine
- 13.4 Legal Regulation of Opioids
- 13.5 Side Effects
- 13.6 Adjuvant Medications
- 13.7 Opioid Market Analysis
- 13.7.1 OxyContin
- 13.7.1.1 Abuse-Resistant OxyContin
- 13.7.1.2 Generic Competition
- 13.7.2 Duragesic
- 13.7.3 Kadian
- 13.7.4 Ultracet/Ultram
- 13.7.5 Avinza
- 13.7.6 Actiq
- 13.7.1 OxyContin
- 13.8 The Future of the Opioid Market
- 13.9 Drivers and Constraints of the Opioid Market
14 TRIPTANS THERAPY MARKET
- 14.1 Overview
- 14.2 Leading Migraine Therapies
- 14.2.1 Imitrex/Imigran
- 14.2.2 Zomig
- 14.2.3 Relpax
- 14.2.4 Maxalt
- 14.2.5 Frova
- 14.3 Preventive vs. Abortive Therapy
- 14.4 The Future of the Migraine Market
- 14.5 Drivers and Constraints of the Triptan Therapy Market
15 ANTICONVULSANT MARKET
- 15.1 Overview
- 15.2 Leading Anticonvulsants
- 15.2.1 Lyrica
- 15.2.2 Neurontin
- 15.2.3 Topamax
- 15.2.4 Depakote
- 15.2.5 Lamictal
- 15.2.6 Trileptal
- 15.2.7 Tegretol
- 15.3 The Future of the Anticonvulsant Market
- 15.4 Drivers and Constraints of the Anticonvulsant Market
16 COX-2 INHIBITORS AND THE FUTURE
- 16.1 The Fall of Bextra
- 16.1.1 Post-Marketing Reports for Bextra
- 16.1.2 Withdrawal of Bextra
- 16.2 The Fall of Vioxx
- 16.2.1 Repercussions from the Vioxx Withdrawal
- 16.3 Celebrex: Surviving the Fallout
- 16.3.1 Black Box Warning
- 16.4 Cox-2 Pipeline
- 16.4.1 Prexige
- 16.4.1.1 TARGET Assessment
- 16.4.1.2 Future of Prexige
- 16.4.2 Arcoxia
- 16.4.3 Dynastat
- 16.4.1 Prexige
- 16.5 The Future of the Cox-2 Class
- 16.6 Drivers and Constraints of the Cox-2 Market
17 PRODUCTS IN DEVELOPMENT
- 17.1 Key Opioid Products in Development
- 17.1.1 Sufentanil Patches
- 17.1.2 Chronogesic
- 17.1.3 Remoxy
- 17.1.4 Rapinyl
- 17.1.5 Hydromorphone Patches
- 17.1.6 M6G
- 17.2 Key Migraine Pain Therapies in Development
- 17.2.1 AZ-001
- 17.2.2 PRO-513
- 17.2.3 MK-0974
- 17.2.4 Botox
- 17.2.5 Trexima
- 17.2.6 Dysport
- 17.2.7 NovaDel
- 17.2.8 Zogenix
- 17.3 Key Cancer Pain Therapies in Development
- 17.3.1 Rapinyl
- 17.3.2 Remoxy
- 17.3.3 Sativex
- 17.3.4 Ziconatide
- 17.3.5 Chronogesic Pain Therapy System
- 17.3.6 ASICs
- 17.3.7 Xen2174
- 17.4 Key Fibromyalgia Therapies in Development
- 17.4.1 Cymbalta
- 17.4.2 Pristiq (desvenlafaxine)
- 17.4.3 Milnacipran
- 17.4.4 Xyrem (sodium oxybate)
- 17.4.5 Other Fibromyalgia Research Areas
- 17.5 Key Post-operative Pain Therapies in Development
- 17.5.1 LidoPAIN SP
- 17.5.2 Dyloject
- 17.5.3 M6G
- 17.5.4 ROX-888
- 17.6 Key Neuropathic Pain Therapies in Development
- 17.6.1 Fentora
- 17.6.2 NGX-4010
- 17.6.3 NP-1
- 17.6.4 Cannabinor (CB2) IV
- 17.6.5 V3381
- 17.7 Emerging Novel Drug Classes
- 17.8 Comparative Analysis of Emerging Therapies
18 THE ROLE OF DRUG DELIVERY IN EMERGING PAIN THERAPEUTICS
- 18.1 Delivery Options for Pain Therapeutics
- 18.2 Emerging Technologies for Delivery of Pain Therapeutics
- 18.2.1 Delivery Devices
- 18.2.2 More Convenient Administration Routes
19 PROMISING AREAS OF RESEARCH
- 19.1 Natural Painkillers
- 19.2 Peptides
- 19.3 Epibatidine
- 19.4 Willow Bark
- 19.5 Chilli Peppers and Capsaicin
- 19.6 Cannabinoids
- 19.7 Receptors as Gateways
- 19.8 Chromaffin Cells
- 19.9 Homeopathic Remedies
- 19.10 Ion Channels
- 19.10.1 Calcium Channel Blockers
- 19.10.1.1 Case Study: Prialt
- 19.10.2 Sodium Channel Blockers
- 19.10.2.1 Tetrodotoxin
- 19.10.3 Vanilloid Receptors
- 19.10.4 Glutamate Receptor Antagonists
- 19.10.4.1 NMDA-Receptor Antagonists
- 19.10.1 Calcium Channel Blockers
- 19.11 NSRI Agents
20 COMPANY BRIEFS
- 20.1 Abbott Laboratories
- 20.2 Alexza Pharmaceuticals
- 20.3 Alpharma
- 20.4 Altea Therapeutics
- 20.5 Amgen
- 20.6 Anesiva
- 20.7 Aradigm
- 20.8 Argolyn Bioscience
- 20.9 AstraZeneca
- 20.10 Avigen
- 20.11 Bayer Schering
- 20.12 Baxter
- 20.13 Biogen Idec
- 20.14 Biovail
- 20.15 Boehringer Ingelheim
- 20.16 Bristol-Myers Squibb
- 20.17 Cadence Pharmaceuticals
- 20.18 CeNeS Pharmaceuticals
- 20.19 Cephalon
- 20.20 Cerimon Pharmaceuticals
- 20.21 Cipher Pharmaceuticals
- 20.22 CombinatoRx
- 20.23 Cypress Bioscience
- 20.24 Depomed
- 20.25 Durect Corporation
- 20.26 Eisai
- 20.27 Elan Pharmaceuticals
- 20.28 Eli Lilly
- 20.29 Elite Pharmaceuticals
- 20.30 Endo Pharmacuticals
- 20.31 Enhance Biotech (formerly Ardent Pharma)
- 20.32 EpiCept
- 20.33 Evotec Neurosciences
- 20.34 FemmePharma Global Healthcare
- 20.35 Forest Laboratories
- 20.36 GlaxoSmithKline
- 20.37 GW Pharmaceuticals
- 20.38 Horizon Therapeutics
- 20.39 Icagen
- 20.40 Indevus Pharmaceuticals
- 20.41 Innocoll Pharma
- 20.42 Ista Pharmaceuticals
- 20.43 Javelin Pharmaceuticals
- 20.44 Johnson & Johnson
- 20.45 Kalypsys
- 20.46 King Pharmaceuticals
- 20.47 Labopharm
- 20.48 Medtronic
- 20.49 Merck & Co
- 20.50 MGI Pharma
- 20.51 Nastech Pharmaceutical
- 20.52 NeuroCure
- 20.53 Neurocrine Biosciences
- 20.54 NeurogesX
- 20.55 Neuromed Pharmaceuticals
- 20.56 Neurorecovery
- 20.57 NovaDel
- 20.58 Novartis Pharmaceuticals
- 20.59 Noven
- 20.60 Nuvo Research
- 20.61 Organon
- 20.62 PainCeptor Pharma
- 20.63 Pain Therapeutics
- 20.64 Penwest
- 20.65 Pfizer
- 20.66 Pharmos
- 20.67 Phosphagenics
- 20.68 Pozen
- 20.69 ProEthic Pharmaceuticals
- 20.70 Purdue
- 20.71 Questcor Pharmaceuticals
- 20.72 Quigley Pharma
- 20.73 Renovis
- 20.74 Roche
- 20.75 RoxRo Pharma
- 20.76 Sanofi-Aventis
- 20.77 Sepracor
- 20.78 SkyePharma
- 20.79 Sosei
- 20.80 Symbollon
- 20.81 Tanabe Seiyaku
- 20.82 Targacept
- 20.83 TheraQuest Biosciences
- 20.84 TorreyPines Therapeutics
- 20.85 UCB Pharma
- 20.86 Vernalis
- 20.87 Vertex Pharmaceuticals
- 20.88 Victory Pharma
- 20.89 Wex Pharmaceuticals
- 20.90 Wyeth
- 20.91 Xenome
- 20.92 XenoPort
- 20.93 XTL Biopharmaceuticals
- 20.94 YM Biosciences
- 20.95 ZARS Pharma
- 20.96 Zogenix
APPENDICES
- APPENDIX I
- APPENDIX II
- APPENDIX III
TABLES
- Table 1.1 Value of the Pain Market by Therapeutic Class 2004 and 2006 ($ mn)
- Table 1.2 Top 20 Pain Medications Worldwide in 2006 ($ mn)
- Table 2.1 Characteristics and Treatment of Acute vs Chronic Pain
- Table 2.2 Incidence of Pain Conditions in American Households
- Table 3.1 Key Pain Management Drug Classes and Diseases/Conditions Treated
- Table 3.2 NSAID Delivery Routes
- Table 3.3 Traditional NSAIDs
- Table 3.4 The Oxford League Table of Analgesic Efficacy
- Table 3.5 Opioid Delivery Routes
- Table 3.6 Well-Known Narcotic Analgesics
- Table 3.7 Antidepressant Delivery Routes
- Table 3.8 WHO Guidelines for Pain Therapy
- Table 4.1 WFSA Analgesic Ladder
- Table 6.1 Common Etiologies of Neuropathic Pain
- Table 6.2 Drug Interactions of the Agents Used to Treat Neuropathic Pain
- Table 7.2 Popular Medicines for the Treatment of Migraine
- Table 7.3 Preventive Headache Therapies
- Table 7.4 Common Analgesics Prescribed for Mild Migraine Pain
- Table 7.5 Ergot Alkaloid Derivatives for Migraine Pain
- Table 7.6 NSAIDs and Cox-2 Inhibitors for Migraine Pain
- Table 7.7 Triptans for Migraine Pain
- Table 7.8 Patent Expirations for Leading Triptans
- Table 8.1 Cancer Pain and Therapeutic Options
- Table 8.2 Adjuvants to Opioids for Treating Cancer Pain
- Table 8.3 Other Treatments for Cancer Pain
- Table 8.4 Anticonvulsants for Cancer Pain
- Table 9.1 Leading Causes of Years of Life Lost Due to a Disability for Both Sexes of All Ages
- Table 9.2 Financial Impact of Employees Suffering RA
- Table 10.1 Popular Treatments for Fibromyalgia
- Table 11.1 Complementary and Alternative Medicine Use by US Adults (2002)
- Table 11.2 Ten Most Common Complementary and Alternative Therapies (2002)
- Table 11.3 Disease/Condition Most Frequently Treated with Complementary/Alternative Medicines
- Table 12.1 Global Sales of Leading Prescription NSAIDs (Traditional) 2006
- Table 12.2 Cox-2 NSAIDs
- Table 12.3 Prescription and OTC Non-Selective NSAIDs
- Table 12.4 Sales of Advil* 2002-2006 ($mn)
- Table 12.5 Financial Forecast of Ibuprofen Sales 2007-2011 ($ mn)
- Table 12.6 Sales of Aleve 2002-2006 (€ mn)
- Table 12.7 Sales of Aspirin 2005-2006 (€ mn)
- Table 12.8 Sales of Excedrin* 2002-2004 ($ mn)
- Table 12.9 Sales of Voltaren 2003-2006 ($ mn)
- Table 12.10 Financial Forecast of Voltaren Sales 2007-2011 ($ mn)
- Table 12.11 Sales of Mobic 2003-2006 (€ mn)
- Table 12.12 Financial Forecast of Mobic Sales 2007-2011 ($ mn)
- Table 12.13 Adverse Events (%) Occurring in ≥2% of Mobic Patients in a 12-Week Osteoarthritis Placebo and Active-Controlled Trial
- Table 12.14 Financial Forecast of the NSAID Market 2007-2011 ($ mn)
- Table 13.1 Overview of Opioid Analgesics
- Table 13.2 Key Opioid Product Sales 2006
- Table 13.3 Global Sales of OxyContin 2003-2006 ($ mn)
- Table 13.4 Financial Forecast of OxyContin Sales 2007-2011 ($ mn)
- Table 13.5 Percent of US Household Population 12 Years and Older Reporting Past Month Non-Medical Use of Physchotherapeutics
- Table 13.6 Global Sales of Duragesic 2001-2006 ($ mn)
- Table 13.7 Financial Forecast of Duragesic Sales 2007-2011 ($ mn)
- Table 13.8 Global Sales of Kadian 2002-2006 ($ mn)
- Table 13.9 Global Sales of Ultracet/Ultram 2001-2006 ($ mn)
- Table 13.10 Global Sales of Avinza 2003-2006 ($ mn)
- Table 13.11 Global Sales of Actiq 2002-2006 ($ mn)
- Table 13.12 Financial Forecast of Actiq Sales 2007-2011 ($ mn)
- Table 13.13 Financial Forecast of the Global Opioid Market 2006-2006 ($ mn)
- Table 14.1 Sales of Triptan Drugs 2001-2006
- Table 14.2 Sales of Leading Migraine Therapies 2006
- Table 14.3 Sales of Imitrex/Imigran 2001-2006 ($ mn)
- Table 14.4 Financial Forecast of Imitrex/Imigran Sales 2007-2011 ($ mn)
- Table 14.5 Sales of Zomig 2001-2006 ($ mn)
- Table 14.6 Financial Forecast of Zomig Sales 2007-2011 ($ mn)
- Table 14.7 Sales of Relpax 2001-2006 ($ mn)
- Table 14.8 Sales of Maxalt 2001-2006 ($ mn)
- Table 14.9 Sales of Frova 2005-2006 ($ mn)
- Table 14.10 Financial Forecast of Triptans 2007-2011 ($ mn)
- Table 15.1 Leading Anticonvulsants, Global Sales 2006
- Table 15.2 Sales Growth in the Anticonvulsants Market 2001-2006 ($ mn)
- Table 15.3 Leading Anticonvulsants Indications
- Table 15.4 Sales of Lyrica 2001-2006 ($ mn)
- Table 15.5 Financial Forecast of Lyrica Sales 2007-2011 ($ mn)
- Table 15.6 Sales of Neurontin 2001-2006 ($ mn)
- Table 15.7 Sales of Topamax 2001-2006 ($ mn)
- Table 15.8 Financial Forecast of Topamax Sales 2007-2011 ($ mn)
- Table 15.9 Sales of Depakote 2001-2006 ($ mn)
- Table 15.10 Financial Forecast of Depakote Sales 2007-2011 ($ mn)
- Table 15.11 Sales of Lamictal 2001-2006 ($ mn)
- Table 15.12 Financial Forecast of Lamictal Sales 2007-2011 ($ mn)
- Table 15.13 Sales of Trileptal 2001-2006 ($ mn)
- Table 15.14 Sales of Tegretol 2001-2006 ($ mn)
- Table 15.15 Financial Forecast of the Anticonvulsant Market 200-2011 ($ mn)
- Table 16.1 Leading Cox-2 Inhibitors 2004 ($ mn)
- Table 16.2 Sales of Celebrex 2003-2006 ($ mn)
- Table 16.3 Sales of Arcoxia 2003-2006 ($ mn)
- Table 16.4 Post-Bextra Switching Trends
- Table 16.5 Future Sales of Celebrex
- Table 17.1 Migraine Drugs in Development
- Table 17.2 Other Fibromyalgia Treatments in Development
- Table 17.3 Promising Areas of Fibromyalgia Research
- Table 17.4 Key Pipeline Products and Their Potential in Pain Management
- Table 18.1 Most Common Delivery Routes for Pain Therapeutics
- Table 20.1 Alexza' s Pain Therapeutics Pipeline
- Table 20.2 Amgen' s Pain Therapeutics Pipeline
- Table 20.3 Avigen' s Pain Therapeutics Pipeline
- Table 20.4 Cadence' s Pain Therapeutics Pipeline
- Table 20.5 CeNeS Pharmaceuticals' Pain Therapeutics Pipeline
- Table 20.6 Depomed' s Therapeutics Pipeline
- Table 20.7 Durect' s Pain Therapeutics Pipeline
- Table 20.8 Eisai' s Pain Therapeutics Pipeline
- Table 20.9 Elite' s Pain Therapeutics Pipeline
- Table 20.10 Evotec' s Pain Therapeutics Pipeline
- Table 20.11 Horizon' s Pain Therapeutics Pipeline
- Table 20.12 Javelin Pharmaceuticals' Pain Therapeutics Pipeline
- Table 20.13 Kalypsys' Pain Therapeutics Pipeline
- Table 20.14 Pfizer' s Pain Therapeutics Pipeline
- Table 20.15 Pozen' s Pain Therapeutics Pipeline
- Table 20.16 Purdue' s Pain Therapeutics Portfolio
- Table 20.17 Victory' s Pain Therapeutics Pipeline
- Table 20.18 XenoPort' s Pain Therapeutics Pipeline
- Table I Global Sales of Leading Pain Management Drugs 2006
- Table II Key Pipeline Pain Therapeutics
- Table III Acute Pain Pipeline
- Table IV Chronic Pain Pipeline
- Table V Neuropathic Pain Pipeline
- Table VI Post-operative Pain Pipeline
- Table VII Migraine Pain Pipeline
- Table VIII Rheumatoid Arthritis Pain Pipeline
- Table IX Cancer Pain Pipeline
- Table X NSAIDs Affected by Newly Required Warning Labels
GRAPHS
- Graph 1.1 Pain Therapeutics Market Share by Class 2006
- Graph 2.1 Top Causes of Pain
- Graph 7.1 Difference in Prevalence of Migraine Headache among Men and Women by Age
- Graph 9.1 Percentage of Adults with Diabetes, Heart Disease, or High Blood Pressure Who Also Have Arthritis
- Graph 12.1 Prescription NSAID Product Market Share (Traditional vs Cox-2 Inhibitors) 2006
- Graph 12.2 Prescription NSAID Product Market Share 2006
- Graph 12.3 Sales of Advil 2002-2006
- Graph 12.4 Sales of Aleve 2002-2006
- Graph 12.5 Sales of Aspirin 2005-2006
- Graph 12.6 Global Sale of Excedrin 2002-2004
- Graph 12.7 Sales of Voltaren 2003-2006
- Graph 12.8 Sales of Mobic 2003-2006
- Graph 13.1 Global Market Share of Branded Opioid Products 2006
- Graph 13.3 Global Sales of OxyContin 2003-2006
- Graph 13.4 Global Sales of Duragesic 2001-2006
- Graph 13.5 Global Sales of Kadian 2002-2006
- Graph 13.3 Global Sales of Ultracet/Ultram 2001-2006
- Graph 13.7 Global Sales of Avinza 2003-2006
- Graph 13.8 Global Sales of Actiq 2002-2006
- Graph 13.9 Financial Forecast of the Global Opioid Market 2006-2006
- Graph 14.1 Sales of Triptan Drugs 2001-2006
- Graph 14.2 Leading Migraine Therapies, Market Share 2006
- Graph 14.3 Geographic Market Share of Leading Triptan-Based Migraine Therapies 2006
- Graph 14.4 Sales of Imitrex/Imigran 2001-2006
- Graph 14.5 Sales of Zomig 2001-2006
- Graph 14.6 Sales of Relpax 2001-2006
- Graph 14.7 Sales of Maxalt 2001-2006
- Graph 14.8 Sales of Frova 2005-2006
- Graph 15.1 Leading Anticonvulsants, Market Share 2006
- Graph 15.2 Sales Growth in the Anticonvulsants Market 2001-2006 ($ mn)
- Graph 15.3 Sales of Lyrica 2004-2006
- Graph 15.4 Sales of Neurontin 2001-2006
- Graph 15.5 Sales of Topamax 2001-2006
- Graph 15.6 Sales of Depakote 2001-2006
- Graph 15.7 Sales of Lamictal 2001-2006
- Graph 15.8 Sales of Trileptal 2001-2006
- Graph 15.9 Sales of Tegretol 2001-2006
- Graph 16.2 Sales of Arcoxia 2003-2006
- Graph 16.1 Sales of Celebrex 2003-2006
